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ABSTRACT
Sensitivity and resistance of cells to platinum drug
chemotherapy are to a large extent determined by
activity of the DNA damage response (DDR). Com-
bining chemotherapy with inhibition of specific DDR
pathways could therefore improve treatment effi-
cacy. Multiple DDR pathways have been implicated
in removal of platinum-DNA lesions, but it is un-
clear which exact pathways are most important to
cellular platinum drug resistance. Here, we used
CRISPR/Cas9 screening to identify DDR proteins
that protect colorectal cancer cells against the clini-
cally applied platinum drug oxaliplatin. We find that
besides the expected homologous recombination,
Fanconi anemia and translesion synthesis pathways,
in particular also transcription-coupled nucleotide
excision repair (TC-NER) and base excision repair
(BER) protect against platinum-induced cytotoxic-
ity. Both repair pathways are required to overcome
oxaliplatin- and cisplatin-induced transcription ar-
rest. In addition to the generation of DNA crosslinks,
exposure to platinum drugs leads to reactive oxygen
species production that induces oxidative DNA le-
sions, explaining the requirement for BER. Our find-
ings highlight the importance of transcriptional in-
tegrity in cells exposed to platinum drugs and sug-
gest that both TC-NER and BER should be consid-
ered as targets for novel combinatorial treatment
strategies.
INTRODUCTION
Platinum-based chemotherapy is among the most widely
used treatments of solid tumors (1,2). Its anti-cancer po-
tency is due to formation of platinum-DNAadducts,mainly
between adjacent purines generating intrastrand crosslinks
(80–90%), or between bases on opposite strands giving rise
to interstrand crosslinks (ICLs). Cytotoxicity of theseDNA
lesions is thought to be derived from impediment of tran-
scription and replication, which eventually causes cell cy-
cle arrest or apoptosis (3). Three platinum drugs are cur-
rently widely approved for cancer treatment in humans: cis-
platin, carboplatin and oxaliplatin. Platinum chemotherapy
responses vary greatly among different tumor types. Oxali-
platin is exclusively used to treat colon and rectal cancer,
against which the other two drugs lack therapeutic efficacy
(1). This drug specificity is, however, poorly understood.
Genetic variability in drug transport, metabolism and cel-
lular defense systems such as the DNA damage response
(DDR), likely account for differences in tumor sensitivity.
The importance of theDDR is exemplified by testicular car-
cinoma of which the sensitivity to cisplatin correlates with
protein levels of specific DNA repair proteins (4,5).
Cells utilize several DDR pathways to cope with DNA
damage. The choice of the pathway depends on the cell cy-
cle stage, the type of DNA lesion and its genomic location
(6,7). For instance, small nucleobase modifications are re-
paired by base excision repair (BER), initiated by lesion-
specific DNA glycosylases that recognize and remove dam-
aged bases (8,9). Cleavage of the sugar-phosphate back-
bone by APE1 is followed by PARP1-dependent DNA syn-
thesis and ligation, involving the BER-specific polymerase
beta (POLB) and the DNA ligase III-XRCC1 complex.
Helix-distorting lesions, such as UV photoproducts and in-
trastrand crosslinks, are repaired by nucleotide excision re-
pair (NER) (10,11). NER is initiated by two DNA damage
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recognition subpathways: transcription-coupled NER (TC-
NER) and global-genome NER (GG-NER). In TC-NER,
damage is detected by lesion-stalling of RNA polymerase
2 (RNAP2), which triggers recruitment of the UVSSA,
CSB and CSA proteins that are essential for the assem-
bly of downstream NER factors. In GG-NER, lesions are
detected anywhere in the genome by the coordinated ac-
tivity of the UV-DDB and XPC/RAD23B/CETN2 com-
plexes. Both damage detection mechanisms utilize the same
machinery to excise the damaged strand by means of the
ERCC1/XPF and XPG endonucleases. The resulting gap is
then filled in byDNA synthesis and ligation. Double-strand
breaks (DSBs) can be resolved by different repair path-
ways, mainly depending on the type of break and cell cy-
cle phase. Non-homologous end-joining (NHEJ) re-ligates
brokenDNAends in any cell cycle phase, while homologous
recombination (HR) acts only in S/G2 phase and employs
the sister chromatid as repair template (12). Finally, removal
of more complex lesions like ICLs requires the collaborative
effort of multiple DDR pathways. Cell cycle phase dictates
the choice of the particular repair response, but the mech-
anisms are still only partially understood. Briefly, stalling
of a replication fork on an ICL leads to lesion recogni-
tion by the Fanconi anemia (FA) pathway and unhook-
ing of the ICL by DNA incision, generating a DSB (13).
ERCC1/XPF is thought to be the main endonuclease re-
sponsible for ICL unhooking, but other nucleases are likely
also involved (14,15). Translesion synthesis (TLS) fills the
gap opposite of the unhooked crosslink, to generate an in-
tact template for the HR pathway, which repairs the DSB.
The unhooked crosslink is probably repaired byNER. Both
NER and TLS are also implicated in removal of ICLs in
non-replicating cells but themechanism involved is even less
well understood (16,17).
DNA lesions induced by platinum drugs were suggested
to trigger the response of multiple repair mechanisms (2,3).
Given the importance of DDR in removal of platinum-
DNA adducts, much effort has also been put into linking
variations in DNA repair capacity and DDR gene expres-
sion and polymorphisms to platinum drug responses, with
varying success (18). Still, it remains unclear which DDR
pathways are most important in determining cancer cell
sensitivity or resistance. Therefore, we applied CRISPR-
based genetic screening to identifyDDRgenes that sensitize
colon cancer cells to platinum drugs. We show that oxali-
platin and cisplatin strongly inhibit transcription and that,
besides FA, TLS and HR, also TC-NER and BER are es-
sential to protect cancer cells against platinum drug cyto-
toxicity by resolving platinum drug-induced transcription
blockage.
MATERIALS AND METHODS
Cell culture
Colon adenocarcinoma cells DLD-1 (Horizon Discovery)
were cultured in a 1:1 mixture of Roswell Park Memo-
rial Institute-1640 medium (Sigma-Aldrich) and Ham’s F-
10 nutrient mix (Lonza), supplemented with 10% fetal
calf serum (FCS; BioWest), and 1% penicillin/streptomycin
(Sigma-Aldrich). Human embryonic kidney cells HEK-
293T, osteosarcoma cells U2OS, hTERT-immortalized hu-
man fibroblasts VH10, SV40-transformed human fibrob-
lasts C5RO, XP4PA (XPC-deficient) (19), CS1AN (CSB-
deficient) (20), CS1AN complemented with YFP-CSBdel
(21), and XRCC1-YFP expressing MRC-5 were cultured
in a 1:1 mixture of Dulbecco’s Modified Eagle medium
(Lonza) and Ham’s F-10, supplemented with 10% FCS, 1%
penicillin/streptomycin, 2 mM UltraGlutamine (Lonza),
and 0.1 mM MEM Eagle non-essential amino acid solu-
tion (Lonza). All cells were cultured at 37◦C, in 20%O2 and
5% CO2, except for VH10 cells that were cultured at 3% O2.
To generateMRC-5 cells expressingXRCC1-YFP,XRCC1-
YFP cDNA (a gift from Anna Campalans) (22) was cloned
into pLenti-CMV-Puro-DEST (a gift from Eric Campeau
& Paul Kaufman) (23). Following lentiviral transduction,
MRC-5 cells stably expressing XRCC1-YFP were selected
by puromycin and fluorescence-activated cell sorting.
Chemicals
Oxaliplatin and cisplatin (Sigma-Aldrich) were dissolved
in PBS, aliquoted and stored at -20◦C. Treatment concen-
tration and duration are indicated for each experiment.
8-methoxypsoralen (8-MOP, Sigma-Aldrich) dissolved in
DMSO was used in 50 M concentration for 2 h. To in-
hibit PARP, cells were treated for 24 h with 10 Molaparib
dissolved in PBS (Selleckchem). To inhibit POLB, cells were
treated for 24 h with 500 M pamoic acid (Sigma-Aldrich)
dissolved in 200mMNaCl and 20mMTris–HCl. To inhibit
transcription, cells were treated for 1 h with 1 Mflavopiri-
dol (Sigma-Aldrich), dissolved in DMSO. Trolox (Sigma-
Aldrich) was dissolved in ethanol and applied for 24 h prior
to an experiment at a concentration of 600 M.
Generation of knockout cell lines
For genetic screening (Figure 1), 85 populations of DLD-
1 cells, each expressing a unique sgRNA targeting one
out of 43 DNA repair genes (Supplementary Table S1),
were generated by lentiviral transduction. For each gene,
two different sgRNAs complementary to an early exon
were designed (except for XPA which was targeted by
one sgRNA only) using the CRISPR Design Tool (http:
//crispr.mit.edu/) (24). Each separate sgRNA was cloned
into plentiCRISPRv2 (a gift from Feng Zhang) (25), which
was transfected into HEK-293T cells using jetPEI® (Poly-
plus Transfection), together with pMDLg/pRRE, pRSV-
Rev and pMD2.G (gifts from Didier Trono) (26), to
generate lentiviruses. Lentiviral particles were harvested
48 h after transfection and used to transduce DLD-1
cells for 24 h, after which transduced cells were selected
with puromycin. Survival experiments with transduced het-
erogeneous cell populations were performed within four
weeks after transduction. To generate stable knockout
(KO) DLD-1 cell lines, cells were transiently transfected
with plentiCRISPRv2 carrying sgRNAs targeting CSA,
XPF, POLB, PARP1, XRCC1 (Supplementary Table S1)
and CSB (5′-GCGAGGGCTGAACGGGATGG-3′ and
5′-TGGGTGTTACAGTCAGCACC-3′). Transfected cells
were selected by puromycin, clonally expanded andKOwas
verified by immunoblot.
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Figure 1. Oxaliplatin sensitivity of DLD-1 cells with CRISPR-induced
loss-of-function mutations in DNA repair genes. Each dot represents a
cell line stably expressing a unique sgRNA targeting a DNA repair gene as
listed in Supplementary Table S1. Responses to an IC20 concentration of
oxaliplatin (15M) of all cell lines were evaluated byMTT assay in two in-
dependent screens and expressed as percentage cell death of treated versus
untreated cells. Top candidate genes are represented by distinct colors cor-
responding to their main involvement in different DNA repair pathways
(nucleotide and base excision repair, NER and BER; Fanconi anemia,
FA; homologous recombination, HR; translesion synthesis, TLS). Most
top hits were identified by one of two sgRNAs, except XPF, FANCA and
RAD51, which are represented by both sgRNAs. Wild type cells are indi-
cated by the star.
siRNA transfection
siRNA transfections were performed using RNAiMax
(Invitrogen) 2 days before each experiment, ac-
cording to the manufacturer’s instructions. siRNA
oligomers were purchased from GE healthcare: CTRL
(D-001210-05), OGG1 (L-005147-00), and XPA (5′-
CUGAUGAUAAACACAAGCUUAUU-3′).
Tracking of indels by decomposition
Tracking of indels by decomposition (TIDE) (27) was used
to analyze insertion/deletion (indel) frequency in DLD-1
cells transduced with sgRNA lentiviruses. Genomic DNA
was isolated using PureLink® Genomic DNA Mini Kit
(Invitrogen) and a 601–840 base pair fragment spanning
each sgRNA target site was amplified by PCRusing primers
listed in Supplementary Table S2. PCR amplicons were iso-
lated from gel and sequenced to determine indel frequency
using the TIDE web tool (https://tide.nki.nl/).
Cell viability assays
Cellular response to oxaliplatin and cisplatin was measured
by MTT CellTiter 96® non-radioactive cell proliferation
assay (Promega). Cells were seeded at a density of 2500 cells
per well in 96-well plates in triplicate and grown to ∼20%
confluency. Oxaliplatin or cisplatin were added into the
medium at 20% of inhibitory concentration (IC20), which
was determined from dose-response curves applying non-
linear regression (Graph Prism, data not shown). IC20 con-
centration for wild type (WT) DLD-1 cells corresponded
to 15 M of oxaliplatin and 10 M of cisplatin. After 3
days of treatment, residual cell viability was measured by
addition ofMTT solution following the manufacturer’s rec-
ommendations. Absorbance at 490 nm was measured using
GloMax®-Multi Detection System (Promega). For clono-
genic survival assays, 400 cells per well were seeded in 6-
well plates in triplicate. The next day, cells were irradiated
with UV-C (254 nm; TUV lamp, Phillips) or treated with
oxaliplatin for 24 h, at the indicated dose. Cells were fixed
with 50% methanol, 14% acetic acid, and 0.2% Coomassie
Brilliant Blue (Sigma-Aldrich) 7 days later. Colonies were
countedwith colony counterGelCount (OxfordOptronics).
Immunoblotting
Cells were lysed in sample buffer (125mMTris–HCl pH 6.8,
20% Glycerol, 10% 2--mercaptoethanol, 4% SDS, 0.01%
Bromophenol Blue) and boiled for 5 min at 98◦C. Proteins
were separated in SDS-PAGE gels and transferred onto
PVDF membranes (0.45 m, Merck Millipore). After 1 h
of blocking in 5% BSA in PBS-T (0.05% Tween 20), mem-
branes were incubated with primary antibodies in PBS-T
at 4◦C overnight. Antibodies were against CSA (EPR9237,
1:1000, Abcam, ab137033), CSB (E-18, 1:250, Santa Cruz,
sc-10459), XPF (3F2/3, 1:500, Santa Cruz, sc-136153),
XPA (FL-273, 1:250, Santa Cruz, sc-853), POLB (1:2000,
Abcam, ab26343), PARP1 (F1-23, 1:1000, Alexis Biochem-
icals, ALX-804-211), XRCC1 (C-15, 1:500, Santa Cruz,
sc-5903), OGG1 (EPR4664(2), 1:1000, Abcam, ab124741)
and, as loading control, against Ku70 (M-19, 1:1000, Santa
Cruz, sc-1487), Tubulin (B-512, 1:5000, Sigma-Aldrich,
T6074) and Aquarius (1:1000, Bethyl Laboratories, A302-
547A). Anti-mouse, anti-goat and anti-rabbit secondary an-
tibodies, conjugated to CF™680 or CF™770 dyes (Sigma-
Aldrich) were used at a dilution of 1:10 000. Probed mem-
branes were visualized with the Odyssey CLx Infrared
Imaging System (LI-COR Biosciences).
Psoralen crosslinks induction and immunofluorescence
To generate localized psoralen-induced intrastrand
crosslinks and ICLs, U2OS and YFP-CSBdel expressing
CS1AN cells were grown on 24 mm coverslips and treated
with 50 M of 8-MOP for 2 h. A 355-nm UV-A laser, set
at 24% intensity laser power and low (8%) speed, attached
to a PALM laser dissection microscope (Zeiss) equipped
with a 40× 0.60 NA Korr LD Plan Neofluar objective,
was used to activate 8-MOP in a track along cell nuclei.
Irradiated cells were fixed with 2% paraformaldehyde
supplemented with 0.1% Triton X-100 and washed in PBS
buffer (PBS containing 0.15% glycine and 0.5% BSA) after
which immunofluorescence was performed as described
(28). Antibodies used were against CSB (E-18, 1:250,
Santa Cruz, sc-10459), FANCD2 (FI-17, 1:1000, Novus
Biologicals, nb100-316), XPA (FL-273, 1:100, Santa Cruz,
sc-853), H2AX (JBW301, 1:1000, Millipore, 05-636).
Secondary antibodies were conjugated with Alexa Fluor
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488, 555 and 633 (Invitrogen). DAPI vectashield (Vector
Laboratories) was used to mount coverslips. Slides were
imaged using an LSM700 confocal microscope (Zeiss).
Reactive oxygen species evaluation
Levels of cellular reactive oxygen species (ROS) were de-
termined by quantifying the oxidation rate of H2DCFDA
(Invitrogen). VH10 cells were grown on 24 mm coverslips
and treated with 100 M oxaliplatin or cisplatin for 2 h,
or with 10 mM H2O2 for 5 min. Next, cells were incubated
with 10 MH2DCFDA in serum-free medium for 30 min,
PBS washed and incubated with fresh serum-containing
medium. H2DCFDA fluorescence was measured by live cell
imaging using an SP5 confocal laser-scanning microscope
(Leica) and quantified with ImageJ software.
Recovery of RNA synthesis
Recovery of RNA synthesis (RRS) was measured by quan-
tifying 5-ethynyl uridine (EU) incorporation in RNA in
DLD-1 WT and KO cells grown on 24 mm coverslips and
treated with 100 M oxaliplatin or cisplatin for 2 h. Un-
treated cells and cells immediately after treatment, or af-
ter 6 or 22 h, were incubated with 0.33 mM EU for 1 h,
fixed in 3.7% paraformaldehyde and permeabilized with
0.5% Triton X-100 (Sigma-Aldrich). EU incorporation was
visualized using click-it reaction cocktail containing Atto
594 Azide (60 M, Atto Tec.), Tris–HCl (50 mM, pH 7.6),
CuSO4.5H2O (4mM, Sigma-Aldrich) and ascorbic acid (10
mM, Sigma-Aldrich). Slides were imaged using an LSM700
confocal microscope (Zeiss) and EU levels quantified with
ImageJ software.
Fluorescence recovery after photobleaching
Fluorescence recovery after photobleaching (FRAP), us-
ing an SP5 confocal laser-scanning microscope (Leica), was
applied to measure mobility of YFP-CSBdel or XRCC1-
YFP in untreated cells or, as indicated, in cells treated for
6 h with 100, 200 or 400 M oxaliplatin or 100 or 200
M cisplatin, 15 J/m2 UV-C (254 nm) or for 5 min with
10 mM H2O2. Immediately after treatment, YFP fluores-
cence was monitored every 22 ms at 1400 Hz with a zoom
of 12× in a strip of 512 × 16 pixels spanning the nucleus,
until steady state fluorescence was reached. Next, the strip
was photobleached at maximum laser intensity. Fluores-
cence recovery was recorded using low laser intensity every
22 ms until steady-state levels were reached. Measurements
were background-corrected and normalized to average pre-
bleach fluorescence levels set at 100%. At least two indepen-
dent experiments of>12 cells each were performed for each
condition. The immobile fraction (Fimm) of each condition
was determined by normalizing measurements to fluores-
cence intensity immediately after bleaching (I0) and aver-
age fluorescence once recovery was complete in untreated
cells (Ifinal, untr) and treated cells (Ifinal, treat), using the for-
mula: Fimm = 1 – (Ifinal, treat – I0, treat)/(Ifinal, untr – I0, treat) (29).
Statistics
Statistical differences were calculated using an unpaired
one-tailed Student’s t-test.
RESULTS
Multiple DNA repair pathways collectively protect cells
against oxaliplatin
To characterize the exact DDR that acts in response to
oxaliplatin, we used a loss-of-function CRISPR/Cas9 ap-
proach to screen for genes of the major DNA repair path-
ways that are required for survival of oxaliplatin-treated col-
orectal cancer cells. Forty-three genes encoding core pro-
teins involved in the BER, NER, FA, HR, NHEJ and TLS
pathways were selected (Supplementary Table S1). For all
genes, except XPA, two sgRNAs were designed based on
the following criteria: (i) complementarity to two early ex-
ons and not spanning the translation start sites, (ii) the low-
est predicted off-target value, and (iii) the lowest number
of single nucleotide polymorphisms in the target sequence.
For XPA, a single sgRNA previously confirmed to induce a
high KO efficiency, was used. To first determine the KO effi-
ciency of designed sgRNAs, we tested 24 sgRNAs for their
ability to induce indels in their respective target genes. sgR-
NAs and Cas9 were introduced by lentiviral transduction
in DLD-1 cells and indel frequency was determined using
TIDE analysis (27). This showed that efficiency of gene dis-
ruption by at least half of the designed sgRNAs was high
and that these sgRNAs induced indels in over 40% of target
sequences (Supplementary Table S2). These data provided
sufficient proof of concept to proceed by using two sgRNAs
per gene for achieving sufficient knockdown for our screen-
ing purpose.
All designed sgRNAs (Supplementary Table S1) were
transduced together with Cas9 into DLD-1 cells such that
85 cell populations each expressing a unique sgRNA were
established. Next, sensitivity of each cell population to an
IC20 of oxaliplatin (15 M) was determined using MTT vi-
ability assays. Only sgRNAs that conferred more that 50%
cell death (i.e. >2-fold higher than WT DLD-1 cells) in
two independent survival screens were considered as can-
didates for further validation. Among these, sgRNAs tar-
geting genes involved in BER (POLB, POLL and XRCC1),
NER (CSA, XPF and ERCC1), FA (FANCA, FAAP24,
SLX4, XPF and ERCC1), HR (MRE11, RAD50, RAD51,
BRCA1 and BRCA2) and TLS (REV3) were identified as
top hits (Figure 1A), showing that oxaliplatin lesions are
likely processed bymultipleDDRpathways. Given the well-
established role of FA and HR in the removal of ICLs (13),
the identification of several genes involved in these path-
ways confirmed the validity of the screen. Also, loss of the
REV3 subunit of Pol TLS polymerase, which is thought to
act in the FA pathway, was shown before to confer strong
sensitivity to ICL-inducing agents (30,31). Likewise, loss
of ERCC1/XPF endonuclease activity, which is critical for
both theNER and FA pathways (14,15,32), was expected to
lead to strong oxaliplatin sensitivity. However, to our sur-
prise, sgRNA targeting the TC-NER gene CSA strongly
sensitized cells to oxaliplatin to the same degree as sgR-
NAs targeting ERCC1/XPF and HR and FA genes. In-
triguingly, the same strong oxaliplatin hypersensitivity was
observed in cells expressing sgRNAs against BER genes
POLB, POLL (also implicated in NHEJ) andXRCC1 (also
implicated in NER). These results suggest that multiple
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/46/18/9537/5077597 by Erasm
us U
niversity R
otterdam
 user on 23 O
ctober 2018
Nucleic Acids Research, 2018, Vol. 46, No. 18 9541
DNA repair pathways, including BER and TC-NER, act
together to protect cells against oxaliplatin-induced DNA
damage. Given the poorly defined role of TC-NER and
BER in response to platinum drugs, we focused on eluci-
dating their activity in response to oxaliplatin and, in com-
parison, to cisplatin.
Transcription-coupled NER resolves transcription block in
platinum-treated cells
To verify the role of TC-NER, clonalDLD-1 cell lines stably
depleted of TC-NER initiation factors CSA and CSB and
downstream core NER factor XPF were generated, follow-
ing sgRNA and Cas9 transfection (Figure 2A). We did not
identify CSB in the screen but noticed that the sgRNAs we
used yielded variable and low KO efficiency (Supplemen-
tary Figure S1), which is why for the stable CSB KO we
designed new sgRNAs (see material and methods). MTT
viability assays confirmed that loss of TC-NER, i.e. loss
of either CSA or CSB, leads to strong sensitivity to oxali-
platin, as well as to cisplatin, similar as loss of NER in gen-
eral, represented by XPF (Figure 2B and C). We corrob-
orated these results using clonogenic survival assays with
GG-NER-deficient XP-C and TC-NER-deficient CS-B fi-
broblasts, derived fromxeroderma pigmentosumandCock-
ayne syndrome patients, respectively. As expected, both cell
types were strongly sensitive to UV (Figure 2D). Strik-
ingly, however, TC-NER-deficient fibroblasts exhibited a
much stronger sensitivity to oxaliplatin than GG-NER-
deficient fibroblasts (Figure 2E). These results suggest that
cells largely rely on TC-NER activity, and to a lesser extent
on GG-NER, to overcome the cell killing effect of platinum
DNA lesions.
As TC-NER removes DNA damage that blocks RNAP2
elongation, recovery of RNA synthesis (RRS) after DNA
damage induction is commonly used as an indirect indi-
cator of TC-NER activity (33). We therefore measured
RNA synthesis in WT and CSA KO DLD-1 cells at dif-
ferent time points after oxaliplatin and cisplatin treatment
by quantifying incorporation of EU into de novo synthe-
sized RNA. Oxaliplatin and cisplatin both effectively inhib-
ited transcription, which in WT cells recovered fully after
24 h (Figure 3A–D). In contrast, transcription recovery in
CSA KO cells was incomplete after 24 h. These data indi-
cate that both platinum drugs impair transcriptional activ-
ity of cancer cells, hampering cell function and proliferation
if transcription-blocking platinum lesions are not removed
by TC-NER.
CSB binds damaged chromatin in platinum-treated cells de-
pending on transcription
To further confirm the initiation of TC-NER in response
to platinum lesions in living cells, we tested whether the es-
sential TC-NER factor CSB binds to damaged chromatin
after oxaliplatin or cisplatin treatment. To this end, wemea-
sured mobility of YFP-tagged CSB by means of fluores-
cence recovery after photobleaching (FRAP), as decreased
mobility of DNA repair proteins after DNA damage inflic-
tion reflects their involvement in DNA repair (34). In re-
sponse to UV irradiation, only a very small fraction of CSB
immobilizes, likely due to transient DNA interaction and
relatively few lesions that are substrate for TC-NER (35).
Therefore, we used a CSB mutant protein that is not re-
leased from DNA damage because it lacks its C-terminal
ubiquitin binding domain (hereafter referred to as CSBdel)
(21). CSBdel was, in line with previous findings, strongly im-
mobilized after UV irradiation, and, importantly, also af-
ter oxaliplatin or cisplatin exposure, in a dose-dependent
manner (Figure 4A and B). In line with its role in TC-
NER, UV-induced CSBdel chromatin binding is dependent
on active transcription (21). Similarly, we could suppress
the oxaliplatin- and cisplatin-induced CSBdel immobiliza-
tion by inhibitingRNAP2 elongation using flavopiridol (36)
(Figure 4B and Supplementary Figure S2). These results
indicate that CSB becomes bound to damaged chromatin
in response to oxaliplatin or cisplatin in a transcription-
dependent manner, which therefore likely reflects its initi-
ation of TC-NER.
To demonstrate participation of TC-NER in the response
to DNA crosslinks in another manner than through plat-
inum drug exposure, we tested recruitment of CSB to intra-
and interstrand crosslinks induced by UVA-activated 8-
MOP in living cells. To this end, U2OS and YFP-CSBdel
expressing cells were treated with 8-MOP and irradiated
in a local subnuclear region using a 355 nm UVA laser
(17). We observed clear recruitment of FANCD2, an essen-
tial recognition factor within the FA pathway, and XPA,
a central coordinator of the NER pathway, to local laser-
induced DNA damage, as visualized by H2AX staining
(Figure 4C). Recruitment of these factors suggested that
both intra- and interstrand crosslinks were efficiently in-
duced using this method. Notably, CSBdel was also strongly
recruited to these DNA damage sites generated by UVA-
activated 8-MOP, supporting the idea that DNA crosslinks
lead to initiation of TC-NER. Taken together, our results
suggest that DNA crosslinking agents strongly and nega-
tively impact transcriptional activity of cells and emphasize
the importance of TC-NER for survival of cells exposed to
these agents.
Base excision repair is required for resolving platinum drug-
induced transcription blockage
To verify the rather surprising involvement of BER in the
response to platinum drug exposure, we established stable
KO clonal DLD-1 cell lines of core BER factors XRCC1,
PARP1 and POLB (Figure 5A). MTT assays with these
KO cells confirmed that functional loss of BER leads to in-
creased sensitivity to oxaliplatin (Figure 5B) as well as to
cisplatin (Figure 5C). Similarly, cells pre-treated with PARP
inhibitor olaparib or POLB inhibitor pamoic acid showed
hypersensitivity to both drugs (Figure 5D and E), imply-
ing that indeed BER protects cells against platinum drug
treatment. Since platinum drugs have a profound inhibitory
effect on transcription, we tested whether BER, like TC-
NER, is necessary for alleviating platinum drug-induced
transcription interference, by performing RRS. Strikingly,
both POLB KODLD-1 cells as well as DLD-1 cells treated
with POLB inhibitor pamoic acid showed impaired tran-
scription recovery 24 h after oxaliplatin or cisplatin expo-
sure (Figure 5F–I). These data point to the relevance of
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Figure 2. Cells deficient in transcription-coupled NER are sensitive to platinum drugs. (A) Immunoblot showing loss of XPF, CSA and CSB protein
expression in stable knockout (KO) DLD-1 cells as compared to wild type (WT) cells. Ku70 and Tubulin were used as loading controls. (B) MTT assay
showing sensitivity of NER-deficient KO cells to 15 Moxaliplatin. (C) MTT assay showing sensitivity of NER-deficient KO cells to 10 M cisplatin. Cell
viability in (B) and (C) was measured 3 days after drug treatment. Bars denote mean and SEM of 2 independent experiments each performed in triplicate.
(D) Response of NER-proficient human C5RO fibroblasts (WT), TC-NER-deficient CS1AN fibroblasts (CSB-deficient) and GG-NER-deficient XP4PA
fibroblasts (XPC-deficient) to UV-C irradiation and (E) oxaliplatin. Each experimental point represents mean and SEM of 3 (D) or 6 (E) independent
experiments, each performed in triplicate. For all panels, *P < 0.05; **P < 0.01
BER in maintaining transcriptional integrity in cells ex-
posed to platinum drugs.
XRCC1 chromatin binding in platinum-treated cells is par-
tially dependent on transcription
To show that BER is activated upon exposure to plat-
inumdrugs, we used FRAP to determine chromatin binding
of YFP-tagged XRCC1 in oxaliplatin and cisplatin-treated
cells. We first determined XRCC1 mobility in cells treated
with H2O2, a potent generator of oxidative lesions that
are substrates for BER (37). As expected, H2O2 induced a
strong XRCC1 immobilization, indicative of BER activity
(Figure 6A). Likewise, we observed clear XRCC1 immobi-
lization upon treatment with oxaliplatin or cisplatin. This
oxaliplatin- and cisplatin-induced XRCC1 immobilization
was reduced in the presence of RNAP2 inhibitor flavopiri-
dol (Figure 6A), suggesting that XRCC1-involved BER ac-
tivity in response to platinum drug exposure is partially
dependent on active transcription. XRCC1 partners with
DNA ligase III and functions in the final ligation step of
BER (38) but possibly also of NER in non-proliferating
cells (39). To discern between its activity in BER and NER
in response to platinum drugs, we measured XRCC1 mo-
bility after RNAi-mediated knockdown of the main BER
glycosylase OGG1 and the NER factor XPA (Supplemen-
tary Figure S3A-B), both acting upstream of XRCC1. As
shown in Figure 6B, XRCC1 immobilization was for the
most part dependent on OGG1 and not XPA, suggesting
that oxaliplatin exposure leads to XRCC1 engagement in a
glycosylase-dependent BER pathway.
Platinum drugs generate oxidative damage
BER is well known to recognize subtle nucleobase mod-
ifications like oxidations. Some DNA glycosylases have
also been implicated in repair of different types of DNA
crosslinks (40–43). However, the observation that platinum
drug-induced XRCC1 chromatin binding is dependent on
OGG1 is striking, because this glycosylase is mainly known
to have affinity for 8-oxoG oxidative lesions and not for
DNAcrosslinks (8). Therefore, we determinedwhether plat-
inum drug exposure could lead to oxidative DNA dam-
age induction that would require BER for its removal, by
testing whether oxaliplatin and cisplatin treatment might
lead to generation of ROS. ROS production was evalu-
ated using the fluorescent ROS indicator H2DCFDA (44),
in slowly dividing VH10 fibroblasts grown in low oxygen.
ROS generation by H2O2 exposure, as control, led to strong
induction of H2DCFDA fluorescence (Figure 6C). Inter-
estingly, also oxaliplatin and cisplatin treatment increased
H2DCFDA fluorescence, suggesting that exposure to these
platinum drugs leads to intracellular ROS production. To
test whether BER is indeed initiated by oxidative dam-
age generated after platinum drug exposure, we measured
XRCC1 mobility in H2O2 and platinum drug-treated cells
following pre-treatment with the antioxidant trolox. Trolox
pre-treatment significantly reduced ROS production after
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Figure 3. Transcription-coupledNER is required for transcription recovery in platinum-treated cells. (A) Recovery of RNA synthesis (RRS), as determined
by quantification of EU incorporation at the indicated time points, in DLD-1 wild type (WT) and CSA knockout (CSA KO) cells after 2 h treatment with
100 M of oxaliplatin. (B) Representative pictures of the oxaliplatin RRS. (C) RRS in DLD-1 WT and CSA KO cells after 2 h treatment with 100 M
of cisplatin. (D) Representative pictures of the cisplatin RRS. Bars represent mean EU signal and SEM of >100 cells from two independent experiments
normalized to untreated control for each cell line, set at 100%. For all panels, *P < 0.05; **P < 0.01
H2O2 exposure (Supplementary Figure S4) and also signif-
icantly reduced H2O2-dependent XRCC1 immobilization
(Figure 6D). In a similar manner, trolox pre-treatment sig-
nificantly reducedROS production after oxaliplatin and cis-
platin exposure (Supplementary Figure S4) and decreased
platinum drug-induced XRCC1 immobilization. These ob-
servations indicate that exposure of cells to platinum drugs
not only induces DNA crosslinks that impair cellular func-
tion, but also leads to generation of oxidative DNA lesions
via ROS production. This likely explains why BER protects
cells against platinum drug exposure.
DISCUSSION
Cisplatin is widely administered as standard chemothera-
peutic agent in cancer treatment, but was replaced by the
more effective oxaliplatin in treatment of advanced colorec-
tal cancer (CRC) (1). CRC is associatedwith increased chro-
mosomal ormicrosatellite instability, the latter being caused
by defective DNA mismatch repair (MMR). We expected
that CRISPR/Cas9 gene editing would be less efficient in
chromosomally unstable cells than in MMR-deficient cells,
due to their intrinsic aneuploidy and copy number varia-
tions. We therefore chose MMR-deficient DLD-1 cells for
our loss-of-function screen. MMR itself does not appear
to be involved in the DDR to oxaliplatin (45), which is
why MMR genes were also not included in the screen. Our
screening suggests that an intricate DDR response protects
CRC cells against oxaliplatin, involving multiple DNA re-
pair pathways including FA, HR, TLS, TC-NER and BER,
which likely results from the large spectrum of lesions in-
duced by this drug. Oxaliplatin, as well as cisplatin, cova-
lently binds to DNA to form various DNA crosslinks, such
as Pt-GpG (60–65%), Pt-ApG (25–30%), Pt-GNG (5–10%)
and ICLs (1–6%), in addition to monofunctional adducts
(2%) and DNA-protein crosslinks (1–3,46). It is therefore
not surprising that genes from all repair pathways known
to deal with DNA crosslinks, namely FA, HR, TLS and
NER, were identified. Nevertheless, the specific identifica-
tion ofCSA, essential for TC-NER, but notXPC orDDB2,
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Figure 4. CSB is recruited to chromatin in platinum-treated cells in a transcription-dependent manner. (A) Fluorescence recovery after photobleaching
(FRAP) analysis of YFP-CSBdel, showing reduced mobility after 15 J/m2 UV-C or 200 M cisplatin (cis; applied for 6 h), depending on transcription
which was blocked by RNA polymerase II inhibitor (RNAP2i) flavopiridol (1 M applied for 1 h). The reduced mobility represents the fraction of CSB
bound to chromatin and involved in active DNA repair. (B) Percentage immobile fraction, i.e. chromatin-bound fraction, of CSBdel after DNA damage
induction as determined by FRAP analyses such as shown in (A). Cells were irradiated with 15 J/m2 UV-C or treated for 6 h with either 100 or 200 M
oxaliplatin (oxa) or cisplatin (cis) without or with 1 h pre-treatment with 1 M RNA polymerase II inhibitor (RNAP2i) flavopiridol, as indicated. Bars
represent mean and SEM of at least 24 cells analyzed in 2 independent experiments. (C) Immunofluorescence showing localization of FANCD2, XPA and
YFP-CSBdel to sites of intra- and interstrand crosslinks (visualized by H2AX staining), introduced by UVA-laser activation of 8-methoxypsoralen (50
M). For all panels, *P < 0.05; **P < 0.01
essential for GG-NER, was striking. This suggests that
TC-NER, and thus transcriptional integrity, is more im-
portant to cellular survival after oxaliplatin exposure than
GG-NER. This was further confirmed by our oxaliplatin
survival experiments with patient-derived NER-deficient fi-
broblasts, which, in line with previously reported similar
cisplatin survival experiments (16,47,48), shows that TC-
NER-deficient cells are sensitive to platinum drugs but GG-
NER-deficient cells are not.
The interference of ICLs with replication is often consid-
ered as the major cytotoxic mechanism through which plat-
inum drugs exert their anti-tumor efficacy. Our results, how-
ever, emphasize that oxaliplatin and cisplatin both strongly
suppress transcription as well, in line with previous litera-
ture (49–51) and that functional TC-NER is critical to over-
come this transcription block. Thus, platinum drug cyto-
toxicity may as well be exerted through inhibition of tran-
scription, as is also suggested before (2). Notably, the oxali-
platin and cisplatin sensitivity of TC-NER-deficient CSA
and CSB knockout CRC cells was equal to that of cells
knockout for XPF, i.e which lack functional GG- and TC-
NERand ICL repair due toXPF’s critical role in these path-
ways (15,32). This highlights the relevance of TC-NER in
platinum drug resistance. CSBdel was immobilized by both
oxaliplatin and cisplatin and recruited to damage gener-
ated by UVA-activated 8-MOP, similar as previously ob-
served for UVA-activated trioxsalen (52). From these ex-
periments, it cannot be distinguished whether CSB acts
on either platinum–DNA intrastrand crosslinks or ICLs
or on both. As plasmid-based reporter assays in human
cells have shown that platinum-DNA intrastrand crosslinks
block RNAP2 (53) and that replication-independent repair
of cisplatin-ICLs specifically depends on CSB (16), it is
likely that TC-NER acts on both types of lesions (Figure 7).
Platinum drugs also crosslink proteins to DNA (46), which
may interfere with transcription (54). Recently, a new repair
pathway was identified that proteolytically processes these
DNA-protein crosslinks, leaving a small peptide-DNA rem-
nant that could possibly be repaired by NER (55–57). It
would be interesting to determine whether TC-NER, rather
than GG-NER, acts specifically on such substrates as well.
A role for BER in resistance of cancer cells to platinum
drugs has previously been suggested (58–62). However, our
observation that in isogenic cells BER appears equally crit-
ical as other DDR pathways indicates that the importance
of BER in protecting against platinum drugs may be gener-
ally underappreciated. PARP1, XRCC1 and POLB, whose
inactivation rendered cells hypersensitive to oxaliplatin and
cisplatin, have been implicated in other repair pathways be-
sides BER as well (39,63–65). Therefore, their involvement
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Figure 5. Base excision repair helps to resolve platinum-induced transcription blockage. (A) Immunoblot showing loss of POLB, PARP1 and XRCC1
protein expression in stable knockout (KO) DLD-1 cells as compared to wild type (WT) cells. Ku70 and Tubulin were used as loading controls. (B) MTT
assay showing sensitivity of BER-deficient KO cells to 15 Moxaliplatin. (C) MTT assay showing sensitivity of BER-deficient KO cells to 10 Mcisplatin.
(D and E) MTT assays showing sensitivity of DLD-1 cells treated with 10 M of PARP inhibitor olaparib (PARPi) or 500 M POLB inhibitor pamoic
acid (POLBi) to 15 M oxaliplatin or 10 M cisplatin, respectively. Cell viability in (B-E) was measured 3 days after drug treatment. Bars denote mean
and SEM of 2 independent experiments each performed in triplicate. (F) Recovery of RNA synthesis (RRS) in DLD-1 wild type (WT) and BER-deficient
cells, either by POLB knockout (KO) or by application of the POLB inhibitor pamoic acid (POLBi). EU incorporation was quantified at the indicated time
points following 2 h treatment with 100 Mof oxaliplatin. (G) Representative pictures of the oxaliplatin RRS. (H) RRS in DLD-1WT and BER-deficient
cells exposed to 100 M of cisplatin for 2 h. (I) Representative pictures of the cisplatin RRS. Bars represent mean EU signal and SEM of >100 cells from
2 independent experiments normalized to untreated control for each cell line, set at 100%. Figures show representative RRS pictures. For all panels, * P <
0.05; ** P < 0.01
may not necessarily imply that (only) BER is engaged in
response to platinum drugs. However, BER involvement
was confirmed by the fact that platinum drug-induced im-
mobilization of XRCC1 was predominantly dependent on
OGG1, a glycosylase exclusively implicated in BER (66).
Some DNA glycosylases, like NEIL1 and NEIL3, have
been shown to recognize and cleave psoralen-induced ICLs
(40,42,43) and also the MPG glycosylase has been im-
plicated in protection against ICL induction by various
crosslinking agents (41,67). Possibly, OGG1 may also rec-
ognize platinum-induced DNA crosslinks and BER could
protect against platinum drugs by recognizing and remov-
ing platinum-DNA lesions via OGG1. However, in agree-
ment with previous reports (68–70), we found that both ox-
aliplatin and cisplatin exposure leads to strongly increased
intracellular ROS levels, likely as a consequence of damage
to mitochondria (71) or an interaction with DNA (72) or
glutathione (73). Importantly also, platinum drug-induced
XRCC1 immobilization could be suppressed by antioxidant
pre-treatment. This, together with dependence on OGG1,
which is well known as glycosylase dealing with 8-oxoG ox-
idative lesions that are predominantly formedwhen cells are
exposed to oxidative stress (8), suggests that BER mainly
protects against platinumdrug cytotoxicity by removing ox-
idative DNA lesions (Figure 7).
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/46/18/9537/5077597 by Erasm
us U
niversity R
otterdam
 user on 23 O
ctober 2018
9546 Nucleic Acids Research, 2018, Vol. 46, No. 18
Figure 6. XRCC1 chromatin retention upon platinum treatment is partially dependent on transcription. (A) Percentage XRCC1-YFP immobile fraction,
i.e. chromatin-bound fraction, as determined by FRAP in MRC-5 cells, after treatment for 5 min with 10 mM hydrogen peroxide (H2O2), 6 h with 400
M oxaliplatin (oxa), 6 h with 200 M cisplatin (cis) without or with 1 h pre-treatment with 1 MRNA Polymerase II inhibitor (RNAP2i) flavopiridol,
as indicated. Bars represent mean and SEM of at least 24 cells analyzed in two independent experiments. (B) Percentage XRCC1-YFP immobile fraction
determined by FRAP after 6 h exposure to 400 M oxaliplatin of MRC-5 cells treated with control siRNA (siCTRL) and siRNA against XPA (siXPA)
and OGG1 (siOGG1). Bars represent mean and SEM of at least 24 cells analyzed in 2 independent experiments. (C) Induction of reactive oxygen species
(ROS) by 10 mM H2O2 applied for 5 min, and 100 M oxaliplatin or cisplatin applied for 6 h in VH10 cells, as measured by H2DCFDA fluorescence.
Figure shows representative confocal pictures and quantification of fluorescence signal of >100 cells from 2 independent experiments represented by the
mean and SEM. (D) Percentage XRCC1-YFP immobile fraction, as determined by FRAP in MRC-5 cells, after treatment for 5 min with 10 mM H2O2,
6 h with 400 M oxaliplatin (oxa) or 6 h with 200 M cisplatin (cis) without or with 24 h pre-treatment with 600 M trolox, as indicated. Bars represent
mean and SEM of at least 24 cells analyzed in two independent experiments. For all panels, *P < 0.05; **P < 0.01; ***P < 0.001
Intriguingly, platinum drug-induced XRCC1 immobi-
lization was partially dependent on transcription and plat-
inum drug-induced transcription arrest was only recovered
in the presence of functional BER. This suggests that BER
is needed to eliminate DNA lesions that interfere with tran-
scription. Nonetheless, apart from sporadic cyclopurines, it
is still debated whether the majority of oxidative lesions,
including 8-oxoG, can effectively block RNAP2 (74–79).
It may also be that intermediate BER products, such as
single-strand breaks and abasic sites, constitute the real bar-
rier to transcription (74,80) (Figure 7). Apart from acting
directly on platinum-DNA crosslinks, the TC-NER pro-
tein CSB may have a role in resolving these transcription
blocks as well, as CSB is recruited to oxidative lesions in a
transcription-dependent manner (81), to promote XRCC1
recruitment (82).
Based on our analysis, we conclude that interference with
transcriptional integrity is one of themajor cytotoxic effects
of platinum drugs. Recently, differences in cytotoxicity pro-
file and clinical application of oxaliplatin and cisplatin were
attributed to differences in cell killing mechanisms, with cis-
platin being classified as DNA crosslinker and oxaliplatin
as transcription/translation inhibitor, killing cells through
ribosome biogenesis stress (83). We did not observe obvi-
ous differences between both drugs in transcription inhibi-
tion and TC-NER or BER involvement. It is not exactly
known whether platinum drugs inhibit RNA polymerase I,
but TC-NER proteins CSA and CSB have both been impli-
cated in RNA polymerase I transcription of rRNA (84,85).
It is therefore likely that TC-NER is also necessary for re-
pair of RNA Polymerase I transcription-blocking lesions
explaining why oxaliplatin exposure leads to ribosome bio-
genesis stress. In any scenario, cancer cells are strongly de-
pendent on the function of TC-NER and BER to overcome
transcription stress. This may be of clinical relevance, as
tumor relapse after chemotherapy is attributed to intrinsi-
cally resistant and quiescent-like cancer stem cells refrac-
tory to treatment (86). Since such cells do not rapidly pro-
liferate, they may be more susceptible to transcription in-
terference than to replication arrest and may therefore rely
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Figure 7. Model depicting the DNA damage response to platinum drug
exposure. Platinum drugs like cisplatin and oxaliplatin induce DNA in-
terstrand and intrastrand crosslinks and lead to the production of re-
active oxygen species (ROS) that induce oxidative lesions. Bulky DNA
crosslinks can directly block RNA polymerase II, inhibiting transcription,
and need to be dealt with by Fanconi anemia (FA), homologous recombi-
nation (HR), transcription-coupled nucleotide excision repair (TC-NER)
and translesion synthesis (TLS) DNA repair and tolerance pathways. Ox-
idative lesions are processed by base excision repair (BER). Transcription
is inhibited either directly by oxidative lesions or by BER intermediate aba-
sic sites or single-strand breaks.
more on DNA repair processes like TC-NER and BER
that maintain transcription. Furthermore, a major draw-
back of the clinical application of platinum drugs is their
acute and chronic side toxicity, in particular to post-mitotic
cells like peripheral neurons, limiting treatment dose and
duration (87). Importantly, cisplatin and oxaliplatin were
found to accumulate in DNA in rat peripheral neurons in
vivo, strongly inhibiting transcription (88,89). This, together
with the notion that transcription defects lead to neuronal
degeneration (11) indicates that transcription impairment
by platinum-DNA adducts is a plausible cause for their spe-
cific side toxicity to post-mitotic cells. It would therefore be
beneficial to better understand exact transcription-coupled
DDR mechanisms in cancer stem cells and post-mitotic
neuronal cells, to be able to improve efficacy of platinum
drug treatment and prevent unwanted side effects.
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